CPhI has released findings of part three of the 2016 CPhI Annual Report, which focuses on growth opportunities over the next 5-years—specifically generics consumption and approval process, the use of big data in pharma and the potential of 3D printed formulations. Four experts—Alan Sheppard, Bikash Chatterjee, Emil Ciurczak and Dilip Shah—examine the implications on clinical trial design, generic drug time to market and even the ‘holy grail’ of individualized patient dosage forms. The overall...